#oncology - Techseriesinsight

August 19, 2025
Business Wire
Biotechnology, Healthcare, News

Twist Bioscience Oncology DNA CGP Panel

Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launched the Twist Oncology DNA Comprehensive Genomic...

July 8, 2025
Business Wire
Biotechnology, Healthcare, News

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 45,000 shares...

VIOME COLLABORATES WITH MICROSOFT TO DELIVER PREVENTIVE HEALTHCARE

June 27, 2025
PRNewswire
Healthcare, News

RaySearch Unveils RayCare v2025, Boosting Cancer Care Efficiency

RayCare v2025 introduces several key innovations designed to simplify daily work for oncology professionals. Seamless integration with Microsoft Word now allows users to generate and update patient-related documents directly...

June 18, 2025
PRNewswire
Healthcare

START Launches Hope Hub to Connect Patients, Physicians, and Advocacy Groups to Community-Based Cancer Trials

The START Center for Cancer Research (“START”), the world’s largest early-phase community-based cancer trial site network, today announced the launch of the START Hope Hub, a powerful new digital patient...

June 17, 2025
PRNewswire
Healthcare

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

Citius Oncology, Inc. (“Citius Oncology”) (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (“Citius Pharma”) (Nasdaq: CTXR), today announced that preparations for the commercial launch of LYMPHIR™, an FDA-approved immunotherapy...

June 5, 2025
PRNewswire
Healthcare

Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited (NASDAQ: KZIA) (“Kazia” or the “Company”), an oncology-focused biotechnology company developing innovative therapies for difficult-to-treat cancers, today announced that the first patient has been dosed in a...

May 30, 2025
PRNewswire
Biotechnology

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the expansion of its precision oncology portfolio. The additions include new test offerings for solid tumor and...

May 27, 2025
PRNewswire
Biotechnology

KAHR Bio Announces Oral Presentation of Phase 2 Study of DSP107 in Combination with anti-PD-L1 in Colorectal Cancer at 2025 ASCO Annual Meeting

KAHR, a clinical-stage biotech company developing DSP107, a first-in-class bi-specific 4-1BB T-cell engager that activates innate and adaptive immunity to treat solid tumors, today announced that positive results from...

May 23, 2025
PRNewswire
Healthcare

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep’s Unique Immune Activation Capabilities

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced new data from the Phase I/II GOBLET clinical trial in a poster presentation...

May 23, 2025
PRNewswire
Biotechnology

SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress 2025

SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, today announced that two abstracts on izalontamab brengitecan (iza-bren), a potentially first-in-class EGFRxHER3 bispecific antibody drug conjugate (ADC) will be presented at...